Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-05-15Clinical Trial Update: T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma [Phase 1]
Phase 1 trial evaluating T cells engineered to express a fully-human anti-BCMA CAR for treating multiple myeloma; results were posted in 202…
-
CLINICAL_TRIALS trial_result · 2023-05-15Clinical Trial Update: Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 trial evaluating mitoxantrone hydrochloride liposome injection for relapsed/refractory multiple myeloma is underway with unknown s…
-
CLINICAL_TRIALS trial_result · 2023-05-06Clinical Trial Update: Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM [Phase 3]
Phase 3 trial comparing elotuzumab with carfilzomib, lenalidomide, and dexamethasone (E-KRd) versus KRd in newly diagnosed multiple myeloma;…
-
CLINICAL_TRIALS trial_result · 2023-04-28Clinical Trial Update: Daratumumab in Combination With ATRA [Phase 1, Phase 2]
Phase 1/2 trial evaluating daratumumab in combination with ATRA in multiple myeloma has completed.
-
CLINICAL_TRIALS withdrawal · 2023-04-28Clinical Trial Update: Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients [Phase 4]
Phase 4 trial assessing bortezomib (Alvocade) in newly diagnosed multiple myeloma was withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-04-27Clinical Trial Update: Reduced Intensity Conditioning Transplant Using Haploidentical Donors [Phase 2]
Phase 2 clinical trial investigating reduced intensity conditioning transplant using haploidentical donors for various hematologic malignanc…
-
CLINICAL_TRIALS trial_result · 2023-04-27Clinical Trial Update: Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance [Phase 3]
Phase 3 trial comparing RAD vs VRD induction in newly diagnosed multiple myeloma with response-adapted consolidation and lenalidomide mainte…
-
CLINICAL_TRIALS trial_result · 2023-04-20Clinical Trial Update: Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM [Phase 1, Phase 2]
A clinical trial update reports on the safety and efficacy of anti-GPRC5D CAR-T cell therapy for relapsed or refractory multiple myeloma acr…
-
CLINICAL_TRIALS trial_result · 2023-04-18Clinical Trial Update: Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]
An update on safety and efficacy of a BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma from Phase 1/Phase 2 trials.
-
CLINICAL_TRIALS trial_result · 2023-04-12Clinical Trial Update: Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies [Phase 1]
Phase 1 trial updating safety, tolerability, pharmacokinetics, and efficacy of AMG 397 in relapsed or refractory hematological malignancies;…
-
CLINICAL_TRIALS trial_result · 2023-04-12Clinical Trial Update: Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
A clinical trial update for an anti-CD38 antibody drug conjugate in relapsed or refractory multiple myeloma spanning Phase 1 and Phase 2, cu…
-
CLINICAL_TRIALS trial_result · 2023-04-07Clinical Trial Update: The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients [Phase 3]
Phase 3 clinical trial evaluating the efficacy and safety of adding colchicine to conventional therapy for multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2023-04-04Clinical Trial Update: Expanded Natural Killer (NK) Cells for Multiple Myeloma Study [Phase 1, Phase 2]
Phase 1/2 study investigating expanded natural killer (NK) cells for multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2023-04-03Clinical Trial Update: Pedometer Activity Monitoring After ASCT [Phase 2]
Phase 2 clinical trial evaluating pedometer-based activity monitoring after autologous stem cell transplantation in lymphoma and myeloma pat…
-
CLINICAL_TRIALS trial_result · 2023-03-27Clinical Trial Update: An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma [Phase 3]
Phase 3 trial evaluating nivolumab, pomalidomide, and dexamethasone in multiple myeloma has completed with posted results.
-
FDA approval · 2023-03-24FDA Approved: POMALYST — Supplemental Application (Celgene Corporation)
FDA approved a supplemental application for POMALYST (pomalidomide) from Celgene Corporation.
-
FDA approval · 2023-03-24FDA Approved: LENALIDOMIDE — Supplemental Application (Apotex Corp.)
FDA approved Apotex Corp.'s supplemental application for lenalidomide (ANDA211022), authorizing the marketing of a generic lenalidomide prod…
-
FDA approval · 2023-03-24FDA Approved: LENALIDOMIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for lenalidomide submitted by Sun Pharmaceutical Industries, Inc.
-
FDA approval · 2023-03-24FDA Approved: LENALIDOMIDE — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for Lenalidomide submitted by Aurobindo Pharma Limited to support the continued availability of …
-
CLINICAL_TRIALS trial_result · 2023-03-24Clinical Trial Update: First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone [Phase 1]
Phase 1 trial update for M3258 (saracatinib-like investigational) in single agent and combination with dexamethasone in multiple myeloma; st…
-
CLINICAL_TRIALS trial_result · 2023-03-23Clinical Trial Update: Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]
A Phase 1/2 study evaluating ipilimumab after stem cell transplantation in relapsed/refractory multiple myeloma was terminated, with results…
-
CLINICAL_TRIALS trial_result · 2023-03-20Clinical Trial Update: INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
A phase 1/2 trial evaluating INCB001158 with subcutaneous daratumumab versus daratumumab SC alone in relapsed or refractory multiple myeloma…
-
CLINICAL_TRIALS trial_result · 2023-03-16Clinical Trial Update: A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin Lymphoma [NA]
A completed clinical trial evaluating an amino acid mixture (Enterade) used during high-dose melphalan conditioning prior to autologous stem…
-
CLINICAL_TRIALS trial_result · 2023-03-09Clinical Trial Update: PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal Function [Phase 2]
Phase 2 clinical trial assessing pharmacokinetics of melphalan during treatment with melflufen and dexamethasone in patients with relapsed/r…
-
FDA approval · 2023-03-08FDA Approved: ZOLEDRONIC ACID — Supplemental Application (Fresenius Kabi USA, LLC)
The FDA approved a supplemental application for zoledronic acid from Fresenius Kabi USA, LLC.